KBI Biopharma, Inc. Releases Inaugural FIH Manufacturing Batch at Integrated Switzerland Facility Five Months After O...
Milestone affirms KBI and Selexis SA’s Geneva cGMP site is operational and running successfully
Read articleMilestone affirms KBI and Selexis SA’s Geneva cGMP site is operational and running successfully
Read articleThe new facility expands the company’s capacity to support both global and local biotech and pharma companies engaged in preclinical and translational oncology drug discovery and development.
Under the initial agreement, Similis will be responsible for cell line development, analytics, process development, and cGMP production, leading to pharmacokinetics/pharmacodynamic clinical trials
Acquisition expands global service offering to include access and analysis of unique clinical biospecimens
KBI Biopharma, Inc. announced it entered into a subcontract with Mapp Biopharmaceutical, Inc. (Mapp) for the continued development and manufacturing of MBP134, an experimental combination monoclona...
Crown Bioscience announced today their newly published study in PLOS ONE demonstrating the establishment and application of a clinically relevant 3D in vitro PDX-derived organoid biobank for higher...
This product detects the SARS-CoV-2 and Influenza virus antigen in nasal swab fluid by the immunochromatography method. MBL can sell this product at pharmacies, drugstores and pharmacy online sites.
Milestone affirms KBI and Selexis SA’s Geneva cGMP site is operational and running successfully
The new facility expands the company’s capacity to support both global and local biotech and pharma companies engaged in preclinical and translational oncology drug discovery and development.
Under the initial agreement, Similis will be responsible for cell line development, analytics, process development, and cGMP production, leading to pharmacokinetics/pharmacodynamic clinical trials
Acquisition expands global service offering to include access and analysis of unique clinical biospecimens
KBI Biopharma, Inc. announced it entered into a subcontract with Mapp Biopharmaceutical, Inc. (Mapp) for the continued development and manufacturing of MBP134, an experimental combination monoclona...
Crown Bioscience announced today their newly published study in PLOS ONE demonstrating the establishment and application of a clinically relevant 3D in vitro PDX-derived organoid biobank for higher...
The new facility expands the company’s capacity to support both global and local biotech and pharma companies engaged in preclinical and translational oncology drug discovery and development.
Acquisition expands global service offering to include access and analysis of unique clinical biospecimens
Crown Bioscience announced today their newly published study in PLOS ONE demonstrating the establishment and application of a clinically relevant 3D in vitro PDX-derived organoid biobank for higher...
Crown Bioscience have signed a global license agreement for access to the foundational CRISPR/Cas9 patent portfolio held by ERS, which provides the company full license to operate globally using CR...
The paper is the first comprehensive review of tumor organoids derived from Patient Derived Xenograft (PDX) models across multiple cancer types.
Crown Bioscience & MBL, a joint venture between two JSR Life Sciences companies formed earlier this year, announce today the launch of their full-service drug discovery and development capabilities...
Milestone affirms KBI and Selexis SA’s Geneva cGMP site is operational and running successfully
KBI Biopharma, Inc. (KBI), a JSR Life Sciences company, today announced its recently expanded, state-of-the-art Geneva mammalian cell manufacturing facility has obtained a Swissmedic regulatory es...
Tim Lowery, President of JSR Life Sciences, has been named as interim CEO to two of our core Group companies, KBI Biopharma, Inc. and Selexis SA. A search for a permanent CEO is underway.
KBI Biopharma, Inc. (KBI) and Selexis SA (Selexis) today announced that Abdelaziz Toumi, Ph.D., will begin serving as the companies’ Chief Business Officer.
Agreement supports the development of molecules targeting acute myeloid leukemia, multiple myeloma, human papilloma virus (HPV) associated tumors, and additional human leukocyte antigens (HLAs) tha...
The KBI and Selexis co-location will expand biopharmaceutical development and manufacturing capabilities to serve the global demand for novel therapies.
Milestone affirms KBI and Selexis SA’s Geneva cGMP site is operational and running successfully
KBI Biopharma, Inc. announced it entered into a subcontract with Mapp Biopharmaceutical, Inc. (Mapp) for the continued development and manufacturing of MBP134, an experimental combination monoclona...
KBI Biopharma, Inc. (KBI), a JSR Life Sciences company, today announced its recently expanded, state-of-the-art Geneva mammalian cell manufacturing facility has obtained a Swissmedic regulatory es...
Tim Lowery, President of JSR Life Sciences, has been named as interim CEO to two of our core Group companies, KBI Biopharma, Inc. and Selexis SA. A search for a permanent CEO is underway.
KBI Biopharma, Inc. (KBI) and Selexis SA (Selexis) today announced that Abdelaziz Toumi, Ph.D., will begin serving as the companies’ Chief Business Officer.
The KBI and Selexis co-location will expand biopharmaceutical development and manufacturing capabilities to serve the global demand for novel therapies.
This product detects the SARS-CoV-2 and Influenza virus antigen in nasal swab fluid by the immunochromatography method. MBL can sell this product at pharmacies, drugstores and pharmacy online sites.
Medical & Biological Laboratories Co., Ltd. successfully acquired regulatory approval on November 11, 2022 for its SARS-CoV-2 antigen test OTC kit “GLINE-2019-nCoV Agキット(一般用).”
Crown Bioscience & MBL, a joint venture between two JSR Life Sciences companies formed earlier this year, announce today the launch of their full-service drug discovery and development capabilities...
This kit detects the SARS-CoV-2 antigen, influenza A virus antigen, and influenza B virus antigen in nasopharyngeal or nasal swab fluid using an immunochromatographic method.
The certification ensures that the CE marked diagnostic products supplied by MBL adhere to standards of quality and safety that ensure the highest level of patients’ health protection
MBL announced that MEBGEN™ BRAF Kit, an in vitro diagnostic reagent, was approved for detection of BRAF gene mutations (V600E or V600K) by the Ministry of Health, Labour and Welfare for production ...
Ajinomoto Co. has reached an agreement with JSR to collaborate on the global expansion of its biopharmaceutical culture media business, adding new high-performance media developed by JSR, to Ajinom...
JSR Corporation announced today that it has entered into a facility usage agreement with AuB, a company engaged in the study of intestinal microbiota in athletes.
JSR Corporation announced today that it has concluded a facility use agreement with KINS Co., Ltd. (KINS), a company with a database of human microbiome.
JSR Life Sciences, LLC is pleased to announce that JSR Corporation and Asahi Kasei Medical have entered into a co-promotion agreement for bioprocess products and materials that initiated sales coll...
JSR Life Sciences that the JSR Corporation has finalized the acquisition of all outstanding shares in MBL. As a result, MBL is a wholly owned subsidiary and affiliate of the JSR Life Sciences famil...
JSR Life Sciences is committed to the advancement of human health worldwide as a strategic partner to companies that discover, develop & deliver products to treat disease & improve quality of life
Crown Bioscience is a global CRO providing preclinical and translational platforms to advance oncology, immuno-oncology, and immune-mediated inflammatory diseases
Selexis is the global leader in mammalian cell line development that leverages best-in-class protein expression technologies & modular workflows to create highly specialized solutions
KBI Biopharma is an award winning CDMO providing fully-integrated, accelerated drug development & biomanufacturing services to pharmaceutical & biotechnology companies globally
MBL is committed to being a leading manufacturer & supplier of diagnostic reagents that facilitate further advances in personalized medicine & individualization of medical care
JSR Corporation's mission is to contribute to social good by supplying materials to serve future generations & providing new value today for their customers & society
Are you a journalist or do you work for a publication?
Sign up and request access to exclusive news.
Find news releases, media kits and clippings